A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL
Status:
Recruiting
Trial end date:
2024-05-31
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, phase IIa study to evaluate the pharmacokinetics (PK),
safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients
with T-PLL. The study consists of two parts. A total of 24-36 T-PLL patients will be
enrolled.